$499 Wegovy and $349 Zepbound: the cash-pay GLP-1 economy, decoded
NovoCare and LillyDirect have each carved out a direct-to-patient channel that brings semaglutide and tirzepatide within reach for uninsured patients. Here's what each program actually costs, what it gets you, and where the ceilings are.
The end of compounded GLP-1s in 2025 created a pricing problem for the uninsured and under-insured patient population. Both Novo Nordisk and Eli Lilly responded with direct-to-patient programs that substantially undercut the list pharmacy price while staying well above compounded-era pricing.
Novo Nordisk: NovoCare Wegovy at $499/month
NovoCare launched in 2025 as a direct-to-patient channel offering branded Wegovy pens at $499/month for eligible uninsured patients. Eligibility: uninsured or with a commercial plan that doesn't cover obesity medications. The program ships pens directly to patients after clinician prescription; no pharmacy markup. Comparison: Wegovy retail list is ~$1,349/month, so the NovoCare price represents roughly a 63% discount from list for the population it serves.
Eli Lilly: LillyDirect Self Pay Zepbound vial at $349-$499/month
LillyDirect's Self Pay program launched in 2024 and expanded in 2025 to include Zepbound in vial form (not the pre-filled pen). Pricing tiers by dose: $349/month for 2.5 mg, $549 for 5 mg, $399-$499 for later-year adjustments. The vial requires the patient to self-measure using an insulin syringe — which lands us back in reconstitution math territory, but for an FDA-approved drug with manufacturer supply chain behind it. Eligibility: uninsured, or commercially insured with no Zepbound coverage.
What these programs don't solve
Medicare Part D patients are still mostly out of luck. Part D's exclusion of obesity drugs as a class limits coverage. The 2024 reforms reduced out-of-pocket caps on covered Part D drugs (meaningful for patients on Ozempic for T2D), but Wegovy for obesity remains broadly excluded.
Medicaid coverage remains patchwork by state. As of April 2026, roughly 20 state Medicaid programs have some Wegovy or Zepbound coverage, typically with heavy prior-authorization requirements (BMI thresholds, documented failure of lifestyle intervention, step therapy). 30 states still don't cover either for obesity.
The telehealth layer
Telehealth providers (Hims, Ro, Henry Meds, MEDVi, Peter MD) have largely migrated to branded Wegovy/Zepbound prescriptions now that compounding is gone. Their role is shifting from "cheap compounded access" to "convenient telehealth consultation + coordination with NovoCare or LillyDirect." For patients, this can mean a consultation fee added to the drug cost — but also simplified navigation of the direct-to-patient programs.
Sources